Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
• Treatments: Amrubicin

Criteria

Inclusion Criteria:

• Extensive-disease small-cell lung cancer

• Aged 70 years or older

• Performance status of 0-2

• No prior chemotherapy

Exclusion Criteria:

• Prior therapy for primary lesion

• Pneumonitis and/or pulmonary fibrosis

• Active concomitant malignancy